Site icon pharmaceutical daily

FDA accepts Novartis’s BLA for acute lymphoblastic leukemia treatment

A sign marks a building on Novartis' campus in Cambridge, Massachusetts, U.S., February 28, 2017. REUTERS/Brian Snyder

A sign marks a building on Novartis' campus in Cambridge, Massachusetts, U.S., February 28, 2017. REUTERS/Brian Snyder

US Food and Drug Administration (FDA) has accepted the Novertis’s Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL).

Novartis said that this is its first BLA submission for a CAR-T.

CAR-T is different from typical small molecule or biologic therapies currently on the market because it is manufactured for each individual patient. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the laboratory to create T cells that are genetically coded to hunt the patient’s cancer cells and other B-cells expressing a particular antigen, the company explained.

“With CTL019, Novartis is at the forefront of the science and development of immunocellular therapy as a potential new innovative approach to treating certain cancers where there are limited options,” said Vas Narasimhan, Global Head of Drug Development and Chief Medical Officer, Novartis. “The priority review and file acceptance of CTL019 by the FDA brings us one step closer to delivering this novel treatment option to children and young adults with r/r B-cell ALL in the United States.”

CTL019 was first developed by the University of Pennsylvania. In 2012, Novartis and the University of Pennsylvania entered into a global collaboration to further research, develop and then commercialize CAR-T cell therapies for the investigational treatment of cancers, including CTL019. Through the collaboration, Novartis holds the worldwide rights to CARs developed through the collaboration with the University of Pennsylvania for all cancer indications.

Safety and efficacy of CTL019 among pediatric and young adult patients with r/r B-cell ALL was tested in US multicenter trial and an earlier single site trial led by the Children’s Hospital of Philadelphia (CHOP).

“Even if a patient has difficult-to-treat relapsed/refractory leukemia, we have seen treatment with CTL019 in clinical trials put cancer into remission,” said Stephan Grupp, Director of the Cancer Immunotherapy Frontier Program and Director of Translational Research for the Center for Childhood Cancer Research at CHOP. “This could be a first-of-its-kind treatment with exciting potential to help pediatric and young adult r/r B-cell ALL patients.”

Novartis said that it plans additional filings for CTL019 in the US and EU markets later this year, including a BLA with the FDA for treatment of adults with r/r diffuse large B-cell lymphoma (DLBCL) and applications for marketing authorization with the European Medicines Agency in r/r B-cell ALL and r/r DLBCL.

 

Exit mobile version